🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 170 of 857 · Phase 3 first, then by program name

  1. Setmelanotide 2 mg

    Rhythm Pharmaceuticals Netherlands B.V.

    Bardet-Biedl Syndrome

    phase 3 small molecule completed

    1 trial

  2. Setrusumab

    Mereo BioPharma Group plc

    Osteogenesis Imperfecta

    phase 3 mab active

    2 trials

  3. Sevabertinib

    Bayer HealthCare AG

    Advanced Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  4. Sevoflurane

    Universal Integrated

    Anesthesia

    phase 3 small molecule completed

    1 trial

  5. Sevoflurano Baxter 100% líquido para inhalación del vapor EFG, Propofol Fresenius 20 mg/ml emulsión inyectable y para perfusión EFG

    The George Institute

    Acute ischemic stroke

    phase 3 small molecule active

    1 trial

  6. Shingrix powder and suspension for suspension for injection Herpes zoster vaccine (recombinant, adjuvanted), Cladribine Placebo, cladribine

    Merck Sharp and Dohme

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  7. Sibeprenlimab 400 mg

    Otsuka Beijing Research Institute

    Immunoglobulin A Nephropathy

    phase 3 small molecule active

    1 trial

  8. Sibeprenlimab 400 mg s.c. Q4weeks

    Otsuka Beijing Research Institute

    Immunoglobulin A Nephropathy

    phase 3 small molecule active

    1 trial

  9. Sigvotatug Vedotin

    Pfizer

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  10. Sildenafil placebo, Remidia, 20 mg, tabletki powlekane

    Cardiol Therapeutics

    Patients with functionally single ventricle (FSV - functionally single ventricle) after Fontan operation. The term "functionally single ventricle" refers to congenital heart defects in which one of the ventricles is not fully developed and/or one of the valves is atresia/hypoplastic as a result, it is not possible to correct the intracardiac defect. Then, there are indications for the Fontan operation, i.e. a palliative procedure - total cavo-pulmonary connection (TCPC). In patients with a functionally single ventricle, more than one operation is necessary to separate the systemic and pulmonary circulation. As a result of these procedures, Fontan circulation is created, which consists in bypassing the right heart chambers and directing the venous blood to the pulmonary artery. This leads to the removal of the right-to-left shunt and improvement of arterial blood saturation and reduction of volume overload of the systemic ventricle. At the same time, there is an increase in systemic venous pressure and a decrease in cardiac output. Low pulmonary resistance in these patients is crucial for maintaining optimal hemodynamic conditions both at rest and especially during exercise. Even a slight increase in pulmonary resistance leads to reduced pulmonary blood flow, reduced initial depression of a single ventricle, and consequently to reduced cardiac output and worsened exercise tolerance. Thus, pulmonary resistance in these patients should be not only normal, but also as low as possible to ensure adequate single ventricular filling and adequate cardiac output. There is evidence that patients with Fontan surgery increase pulmonary resistance over time. The increase in pulmonary resistance in these patients may result from several factors, and above all from the progressive dysfunction of a single systemic ventricle and the lack of a subpulmonary chamber ensuring pulsatile pulmonary flow. Although the Fontan operation in many patients with an univentricular heart is a very good method of palliative treatment, which undoubtedly extends the survival of children born with this heart defect, it also inevitably leads to severe complications developing over the years. Patients after the Fontan operation are also characterized by a significant reduction in exercise capacity, which is observed both in clinical practice in reference centres dealing with patients with congenital heart defects, and in multi-centre studies. Among other things, it was shown that children after the Fontan operation obtained 30% lower values of peak oxygen uptake in the ergospirometric test compared to the control group of healthy children (Amadero P et al., Heart 2018). The reduced exercise capacity of patients and the development of Fontan circulatory complications affect both the quality of life and the prognosis of adult patients with univentricular heart.

    phase 3 small molecule active

    1 trial

  11. Simponi 50 mg solution for injection in pre-filled syringe., Simponi 45 mg/0.45 mL solution for injection in pre-filled pen., Simponi 100 mg solution for injection in pre-filled syringe.

    Janssen-Cilag Pty Ltd

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  12. Simvastatina NORMON 10 mg comprimidos recubiertos con película EFG, Atorvastatina NORMON 20 mg comprimidos recubiertos con película EFG, Simvastatina NORMON 40 mg comprimidos recubiertos con película EFG, Atorvastatina NORMON 40 mg comprimidos recubiertos con película EFG, Atorvastatina NORMON 10 mg comprimidos recubiertos con película EFG, Atorvastatina Normon 60 mg comprimidos recubiertos con película, Simvastatina NORMON 20 mg comprimidos recubiertos con película EFG

    The George Institute

    Spontaneous lobar ICH

    phase 3 small molecule active

    1 trial

  13. Sinovac PCV13

    Sinovac Research and Development Co.,

    Pneumococcal Infectious Diseases

    phase 3 mab active

    1 trial

  14. Sinovac PCV13

    Sinovac Research and Development Co.,

    Pneumococcal Infectious Disease

    phase 3 mab active

    2 trials

  15. Sinovac rabies vaccine

    Sinovac Research and Development Co.,

    Rabies (Healthy Volunteers)

    phase 3 mab active

    2 trials

  16. Sipavibart, SODIUM CHLORIDE, EVUSHELD 150 mg + 150 mg solution for injection, EVUSHELD 150 mg + 150 mg solution for injection

    AstraZeneca AB

    COVID-19

    phase 3 small molecule active

    1 trial

  17. Sirolimus

    Ultragenyx UK Limited

    Lymphangioleiomyomatosis

    phase 3 small molecule completed

    1 trial

  18. Sirolimus

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lupus Nephritis

    phase 3 small molecule active

    1 trial

  19. Sitaxsentan

    Pfizer

    Pulmonary Arterial Hypertension

    phase 3 small molecule terminated

    1 trial

  20. Skilarence 120 mg gastro-resistant tablets, MAGNESIUM STEARATE, MICROCRYSTALLINE CELLULOSE

    The George Institute

    Adrenomyeloneuropathy

    phase 3 small molecule active

    1 trial

  21. Sodio Cloruro Fresenius Kabi Italia 0,9%, solvente per uso parenterale, Samyr placebo (saline solution), SAMYR 400 mg/5ml polvere e solvente per soluzione iniettabile

    Mylan Pharma UK

    Major Depression Disorders

    phase 3 small molecule active

    1 trial

  22. Sodio ioduro (I131) Curium Netherlands 37-7400 MBq capsula rigida, TAPAZOLE 5 mg compresse

    Sana Biotechnology

    Graves' disease and Graves' orbitophaty

    phase 3 small molecule active

    1 trial

  23. Sodium Chloride 0.9% Intravenous Infusion, VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor)

    Viridian Pharma Ltd

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  24. Sodium Oxybate

    Jazz Pharmaceuticals Ireland Limited

    Fibromyalgia

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources